India, May 26 -- Editas Medicine, Inc. (EDIT), a gene editing company developing CRISPR-based medicines, announced the pricing of an underwritten public offering of 55,555,556 shares of common stock and accompanying warrants to purchase an equal number of shares. Each share and warrant are being sold together at a combined public offering price of $2.25.
The offering is expected to generate gross proceeds of approximately $125 million before expenses, assuming no exercise of warrants. If all warrants are exercised at their $3.50 per share exercise price, Editas could receive an additional $194.4 million, bringing the total potential proceeds to $319.4 million.
The warrants will be exercisable immediately and will expire either 30 days aft...